Zhitong Financial App News, Hehuang Pharmaceutical (00013.HK) announced that applications for regulatory registration of Warisha® (savolitinib) and Teresa® (osimertinib) combination therapy in Europe and Japan have been accepted.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.